SCHIZOPHRENIA RESEARCH IN GLASGOW AND BEYOND Nagore Penades - - PowerPoint PPT Presentation

BIPOLAR, DEPRESSION AND SCHIZOPHRENIA RESEARCH IN GLASGOW AND BEYOND

Nagore Penades

Consultant in General Adult Psychiatry Mental Health Partnership Researcher

Commercial/Sponsored Studies

A phase II randomized, double-blinded, placebo- controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily with adjunctive Computerized Cognitive Training over 12 week treatment period in patients with schizophrenia

Commercial/Sponsored Studies

About the Compound: BI 425809 is a GLYT1 inhibitor. Inhibition of GLYT1 increases the concentration of the NMDA receptor co-activator Glycine in the synaptic cleft, which may lead to improvement of negative and cognitive symptoms in patients with schizophrenia and to cognitive improvement in patients with Alzheimer’s Disease.

Commercial/Sponsored Studies

Main Inclusion Criteria

• Male or Female 18-50 years of age
• Diagnosis of Schizophrenia
• Stable with no hospital admissions for 3 months
• Medically stable for over 4 weeks.
• PANSS- No more than “moderate severe” rating on

positive items P1,P3-P7.

• Must have an identified informant

Commercial/Sponsored Studies

Research Team

• Claire Matrunola, Research Assistant
• Murray Sutherland, Research Nurse
• Matt Turner, ST5
• Akkshay Iyer, ST6
• You?

Academic Collaboration ATP Trial: Treatment Resistant Depression

A randomised, placebo-controlled, double-blind trial of the antidepressant efficacy of a novel CNS- penetrant P2X7 receptor antagonist, in people with major depressive disorder, an incomplete response to monoaminergic antidepressant drugs, and a biomarker profile predictive

• f

active P2X7 signalling.

UK multicentre Welcome trust sponsored academic- industry collaboration.

Academic Collaboration ATP Trial: Treatment Resistant Depression

Aim: To evaluate the efficacy of JNJ-54175446, compared to placebo as an adjunctive antidepressant therapy for people with incomplete response to conventional antidepressant drugs and a biomarker profile predictive

• f active P2X7 signalling.

Assessment:

• Objective and subjective evaluation of MMD: MADRS
• Biomarkers for peripheral inflammation (e.g. gene

expression in peripheral blood mononuclear cell)

• Brain imaging.

Academic Collaboration ATP Trial: Treatment Resistant Depression

Inclusion Criteria:

• HDRS17 at screening ≥17.
• Currently being treated with one antidepressant drug

from

• ne
• f

three classes

• f

monoaminergic antidepressant: SSRI, SNRI or TCA

• Antidepressant treatment must have been prescribed at

an adequate dose, and for at least 6 weeks and no more than 24 months.

• In addition, patients may receive stable augmentation

therapy with mirtazapine, low-dose quetiapine (≤150 mg/day), or low-dose amitriptyline (<50 mg/day).

Academic Collaboration ATP Trial: Treatment Resistant Depression

Research Team

• Professor J Cavanagh and Team
• Murray Sutherland, Research Nurse, CRF
• Louise Beattie, Research Assistant
• Akkshay Iyer, ST6
• You?

Pharmacogenomics of response to Lithium

“Towards precision medicine for bipolar disorder: a pilot study of genetic and non-genetic influences on lithium responsiveness”

RQ1.-To what extend does polygenic loading for mood instability influence response to lithium? RQ2.-Does a history of childhood adversity attenuate any

• bserved association between polygenic loading for mood

instability and lithium response?

Pharmacogenomics of response to Lithium

“Towards precision medicine for bipolar disorder: a pilot study of genetic and non- genetic influences on lithium responsiveness”

• 200 Scottish participants with diagnosis of Bipolar

Disorder

• Alda and ACE questionnaires
• GWAS

Pharmacogenomics of response to Lithium

Research Team

• Professor D Smith
• Nagore Penades
• Jacquie McTaggart, Research Nurse, CRF
• Akkshay Iyer, Matt Turner
• You?

Tasks

• Recruitment and Consenting
• Study interviews
• Rating Scales/Questionnaires:
• Alda questionnaire/ACEs questionnaire
• MINI, PANNS, SCoRs, MCCB.....

Time Scales:

• Currently recruiting

Days:

• Mainly Fridays

Covid-Proof Projects

1- Interventional Study: CBT based digital depression and anxiety groups for care workers 2- Outcome Evaluation Study- Digital vs. Traditional groups 3-MyPsych App Evaluation study

Covid-Proof Projects Team: Ever growing Time Scales: Ready to start Tasks:

• Study design and protocol writing
• Funding applications
• Data analysis
• Paper writing

Day of the Week: Flexible

Thank you